Clinical Study Results
Publication of Clinical Study Results
Since 2020, Gilead discloses clinical study results of newly authorized treatments in Switzerland by Swissmedic according to the requirements laid out in Art. 71-73 TPO (Ordinance on Therapeutic Products).
Therapies are listed in alphabetical order.
| Product | Active Substance | Authorization Number | Date of Authorization |
|---|---|---|---|
| Hepcludex® | Bulevirtid | 68338 | 05.02.2024 |
| Sunlenca® | Lenacapavir | 68385 / 68386 | 07.07.2023 |
| Tecartus® | Autologous anti-CD19-transducedCD3+ cells | 67884 | 25.08.2021 |
| Trodelvy® | Sacituzumab govitecan | 68179 | 09.09.2021 |
| Veklury® | Remdesivir | 68026 / 68043 | 25.11.2020 |